论文部分内容阅读
早产儿肺透明膜病(HMD)是由于肺表面活性物质(pulmonary surfactant,PS)不足导致弥漫性肺泡不张、水肿及细胞损伤,由于血浆蛋白漏至肺泡腔更抑制了PS的功能导致肺萎陷,气体交换面积不足出现呼吸困难症状并表现为进行性加剧,近年来对HMD处理的进展方面包括产前对HMD高危儿诊断试验、预防性治疗(包括激素及PS)、围生期处理,尤其呼吸支持的进展及PS的替代性治疗等。
Hypophyseal obstructive pulmonary disease (HMD) in preterm infants results from diffuse alveolar atelectasis, edema and cell damage due to inadequate pulmonary surfactant (PS) leakage of plasma due to leakage of plasma proteins into the alveolar space Inadequacy of gas exchange area showed dyspnea and progressive worsening. Progress in HMD in recent years included prenatal diagnosis of high risk infants with HMD, prophylactic treatment (including hormones and PS), perinatal treatment, Especially respiratory support for the progress and PS alternative treatment.